| Chiu CC |
------>authors3_c= ------>paper_class1=1 ------>Impact_Factor=3.134 ------>paper_class3=2 ------>paper_class2=1 ------>vol=44 ------>confirm_bywho=None ------>insert_bywho=m105091015 ------>Jurnal_Rank=26.9 ------>authors4_c= ------>comm_author= ------>patent_EDate=None ------>authors5_c= ------>publish_day=1 ------>paper_class2Letter=None ------>page2=1390 ------>medlineContent= ------>unit=E0120 ------>insert_date=20090922 ------>iam=3 ------>update_date=None ------>author=??? ------>change_event=1 ------>ISSN= ------>authors_c= ------>score=500 ------>journal_name=J Clin Pharmacol ------>paper_name=Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia ------>confirm_date=None ------>tch_id=093140 ------>pmid=15545309 ------>page1=1385 ------>fullAbstract=Olanzapine, an atypical antipsychotic agent, is a substrate of the cytochrome P4501A2 (CYP1A2) enzyme. Administration of a potent CYP1A2 inhibitor (eg, fluvoxamine) may alter the pharmacokinetics of olanzapine. This study investigated the pharmacokinetic interactions between olanzapine and fluvoxamine in patients with schizophrenia. Ten male smokers were administrated a single dose of olanzapine 10 mg at baseline, followed by 2 weeks of fluvoxamine 50 mg/day and another 2 weeks of fluvoxamine 100 mg/day. Olanzapine 10 mg was given at day 10 during each fluvoxamine treatment. After pretreatment with fluvoxamine, the area under the curve, maximal plasma concentration, and half-time of olanzapine were significantly increased by 30% to 55%, 12% to 64%, and 25% to 32%, respectively. Volume of distribution and apparent clearance were significantly reduced by 4% to 26% and 26% t O 38%, respectively, after administration of fluvoxamine. Increases in area under the plasma concentration-time curve from time 0 to infinity appear to be dose dependent. Presumably, altered olanzapine pharmacokinetics are attributed to the inhibition of CYP1A2. Patients treated with the combination of olanzapine and fluvoxamine should be monitored carefully. ------>tmu_sno=None ------>sno=22244 ------>authors2=Lane HY ------>authors3=Huang MC ------>authors4=Liu HC ------>authors5=Jann MW ------>authors6=Hon YY,Chang WH,Lu ML ------>authors6_c= ------>authors=Chiu CC ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c= ------>publish_area=0 ------>updateTitle=Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia. ------>language=2 ------>check_flag=None ------>submit_date=None ------>country=None ------>no=12 ------>patent_SDate=None ------>update_bywho=None ------>publish_year=2004 ------>submit_flag=None ------>publish_month=12 |